NasdaqCM:HRTXBiotechs
Heron Therapeutics (HRTX) TTM Loss Of US$20.2 Million Tests Profitability Turnaround Narrative
Heron Therapeutics (HRTX) just closed out FY 2025 with Q4 revenue of US$40.6 million and a basic EPS loss of US$0.02, alongside a trailing 12 month revenue base of US$154.9 million and a TTM basic EPS loss of US$0.12. Over recent quarters the company has seen revenue move between US$32.8 million and US$40.8 million, while quarterly basic EPS has ranged from a profit of US$0.02 to a loss of US$0.10. This gives investors a clearer view of how top line scale and per share results have been...